Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 4/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.52 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383734 | 0.88 | FDPS (0.54) | POLA1NR1H2NR1H3 | |
| SCHEMBL31181392 | 0.85 | POLA1 (0.68) | POLA1NR1H2NR1H3KARS1RXRA | |
| SCHEMBL20359348 | 0.85 | POLA1 (0.68) | POLA1NR1H2NR1H3KARS1RXRA | |
| SCHEMBL9296444 | 0.75 | LMNA (0.43) | — | |
| SCHEMBL9296436 | 0.75 | LMNA (0.43) | — | |
| SCHEMBL6391596 | 0.74 | LMNA (0.67) | POLA1NR1H2NR1H3KARS1RXRA | |
| SCHEMBL2985198 | 0.74 | LMNA (0.67) | POLA1NR1H2NR1H3KARS1RXRA | |
| Podocaric Acid SCHEMBL6311820 | 0.73 | NR1H2 (0.80) | POLA1NR1H2NR1H3KARS1RXRA | |
| Podocaric Acid SCHEMBL14389445 | 0.73 | NR1H2 (0.80) | POLA1NR1H2NR1H3KARS1RXRA | |
| Podocaric Acid SCHEMBL31181390 | 0.73 | NR1H2 (0.80) | POLA1NR1H2NR1H3KARS1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175383-B1 | GLUCOCORTICOID RECEPTOR MODULATORS | PFIZER PROD INC (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-1521733-B1 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR | PFIZER PROD INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-7713989-B2 | Glucocorticoid receptor modulators | DOW ROBERT L | 2010-05-11 | — | — | US | disclosed |
| US-7553877-B2 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | PFIZER, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070117805-A1 | Glucocorticoid receptor modulators | PFIZER INC. | 2007-05-24 | — | — | US | disclosed |
| US-7166593-B2 | Glucocorticoid receptor modulators | PFIZER, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7138406-B2 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | PFIZER, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060247264-A1 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | PFIZER INC | 2006-11-02 | — | — | US | disclosed |
| EP-1685110-A1 | OCTAHYDROPHENANTHRENE HYDRAZIDE DERIVATIVES USEFUL AS GLUCOCORTICOID RECEPTOR MODULATORS | Pfizer Products Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1201649-B1 | Glucocorticoid receptor modulators | PFIZER PROD INC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-6852719-B2 | Dietetics; antidiabetic agents; antiinflammatory agents | PFIZER INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040176595-A1 | Glucocorticoid receptor modulators | PFIZER, INC. | 2004-09-09 | — | — | US | disclosed |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | PFIZER INC. | 2004-07-15 | — | — | US | disclosed |
| US-6699893-B2 | DIETETICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATROY AGENTS | PFIZER INC | 2004-03-02 | — | — | US | disclosed |
| US-20040014741-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2004-01-22 | — | — | US | disclosed |
| US-20020147336-A1 | Glucocorticoid receptor modulators | DOW ROBERT L (US) | 2002-10-10 | — | — | US | disclosed |
| US-20020107235-A1 | Glucocorticoid receptor modulators | LIU KEVIN K (US) | 2002-08-08 | — | — | US | disclosed |
| EP-1201649-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1201660-A1 | Glucocorticoid receptor modulators | Pfizer Products Inc. (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6380223-B1 | FOR THERAPY OF DISEASES, SUCH AS OBESITY, DIABETES, INFLAMMATION | PFIZER INC. | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176595-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | POLA1 3294/4885NR1H2 25/4885NR1H3 40/4885 |
| US-20060247264-A1 | Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma | NR3C1, NR3C2, LTB4R2 | POLA1 3429/4885NR1H2 44/4885NR1H3 70/4885 |
| US-20040138262-A1 | Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders | NR3C1, MC2R, FPR1 | POLA1 2585/4885NR1H2 131/4885NR1H3 281/4885 |
| US-20040014741-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | POLA1 3058/4885NR1H2 51/4885NR1H3 69/4885 |
| US-20020147336-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | POLA1 3268/4885NR1H2 25/4885NR1H3 39/4885 |
| US-20020107235-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | POLA1 3064/4885NR1H2 49/4885NR1H3 64/4885 |
| US-20070117805-A1 | Glucocorticoid receptor modulators | NR3C1, NR3C2, MC2R | POLA1 3363/4885NR1H2 25/4885NR1H3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.